93 results about "Ganglion" patented technology

The invention discloses a near-infrared light controllable irradiator for astroganglion stimulation, which comprises a physiological signal acquisition module used for acquiring a near-infrared light sensing signal of a carotid artery area in real time; the signal processing module is used for performing variational mode decomposition on the near-infrared sensing signal and extracting a heart rate component; the autonomic nerve analysis module is used for receiving the heart rate component and calculating the excitement ratio of sympathetic nerves to parasympathetic nerves; a deep learning model is arranged in the control signal generation module, and an optical parameter control signal is generated according to the heart rate cycle characteristics and the excitement ratio; and the light adjusting module is used for receiving the light parameter control signal so as to control the emission of near-infrared light. According to the invention, the output of the infrared light can be adjusted according to the physiological signal of the human body, intelligent adjustment is realized, the near-infrared light stimulation better fits the individual condition, and the pertinence and effectiveness of the stimulation are effectively improved.

An ultrasound-nuclear magnetism / CT registration method for dorsal root ganglion positioning is characterized in that a rib is used as an auxiliary mark of an auxiliary positioning image section, and accurate registration and image fusion of an ultrasound image and a nuclear magnetism / CT image are completed through the characteristic that the relative distance between a transverse process and the rib is fixed. And finally, the purpose of accurately positioning the dorsal root ganglion is achieved. The method is simple and easy to implement, high in accuracy and capable of effectively solving the problem that the dorsal root ganglion cannot be accurately positioned on the ultrasonic image, and the puncture treatment effect of the dorsal root ganglion is improved.

The invention relates to a navigation positioning system for sphenoid palate ganglions. The system comprises a data processing modeling module which is used for acquiring a preoperative multi-modal image data set, extracting sphenoid palate ganglion features of an image, and generating an individualized anatomical model reflecting individual anatomical differences; the path planning module extracts boundary features of a key structure based on an individual anatomical model, generates an acupuncture path set and a candidate path set by adopting a path planning algorithm, and determines optimal acupuncture approach parameters. And the guide track generation module calculates the spatial attitude of the instrument by using a quaternion transformation algorithm according to the optimal acupuncture approach parameters, and generates a dynamic guide track. And the deviation correction updating module predicts a motion track through a Kalman filtering algorithm, calculates a real-time path deviation value, updates output parameters of a navigation system according to the deviation value, and finally generates an acupuncture guide path. By adopting the system, the position difference of the sphenoid palate ganglion and the adjacent tissues thereof can be effectively captured, and a whole-process accurate navigation support is provided for sphenoid palate ganglion acupuncture stimulation.

There is provided a transvenous cryoneurolysis system and method for accessing and targeting neural treatment sites to relieve a variety of clinical indications, including peripheral neuropathy. A neurosome approach is described that includes one or more target nerves to receive selective cryoneurolysis via a target vein. The system performs a variety of freeze-thaw cycles via the target vein to induce a desired axial cryolesion along a target nerve. The target nerves and veins are selected to combine the treatment of the identified neurosome for pain relief in addition to the regenerative properties of cryoneurolysis.

The invention relates to a control method of optical acupuncture, which comprises the following steps: a control system continuously applies a plurality of optical stimulation pulses lower than a nerve excitation threshold value, and target acupuncture point nerves enter a subcritical energy storage state through membrane potential superposition after synapse; laser output intensity is increased, and a directional threshold crossing pulse is emitted to trigger nerve discharge; judging the principal axis direction of local tissue fibers, and adjusting the laser incident angle, so that a light beam penetrates along the principal axis direction to trigger compliant tissue resonance; two beams of frequency differential laser are used for cross irradiation in a non-treatment acupoint area needing suppression to form fixed interference fringes, and a minimum power drop point is calculated to cover and suppress a target acupoint, so that the acupoint is always in an interference offset zone in the treatment process to form a selective function suppression window; a control system synchronously collects heart rate and respiration signals of a user, extracts respective periods to calculate a minimum common rhythm, sets a subsequent light stimulation rhythm as a physiological rhythm differential resynchronization frequency, and enables alternating resonance activation of different neural rhythms through phase staggering.

The invention provides an optic nerve regulation and control system based on an ultrasonic technology, a first ultrasonic module is deployed on the outer side of a target human eyelid and is provided with an Archimedes spiral type first ultrasonic array facing the human eye, and the first ultrasonic array is configured to generate a gathered ultrasonic beam which acts on a human eye retina ganglion cell area in a targeted manner; the positioning module is deployed on the outer side of a target human eyelid and is configured to measure three-dimensional geometric data when a human eyeball horizontally faces the front and measure the depth distance of a human eye retina ganglion cell area in the human eye; the optic nerve response prediction module is pre-trained with an optic nerve response prediction model facing a target human body, and the optic nerve response prediction model is configured to adjust sound intensity output of the first ultrasonic array based on stimulation feedback prediction of human eye retina ganglion cells. According to the invention, the optic nerve regulation and control system satisfies non-intrusive, high-precision and self-adaptive requirements, and has optic nerve regulation and control and repair functions.

The present invention discloses a percutaneous puncture balloon device for compressing both the semilunar ganglion and the third ramus of the trigeminal nerve. The device comprises a catheter, wherein an inner balloon is provided on the outer wall of the catheter near the operating end, and an outer balloon is provided over the inner balloon. The catheter comprises a hollow tubular body, which is divided into an upper cavity and a lower cavity by a partition plate. The sidewall of the upper cavity is provided with an inner vent connected to the inner balloon, and the sidewall of the lower cavity is provided with an outer vent connected to the outer balloon. A rotary cavity switching mechanism is provided at the end of the partition plate away from the balloon for switching between the upper and lower cavities. The inner balloon comprises a balloon body, and an elastic binding membrane layer is provided in the middle of the balloon body. The present invention is characterized by being able to effectively improve the therapeutic effect of patients with pain in the ramus III region.

The present invention provides a biomarker combination for diagnosing Hirschsprung's disease, which is any one of combination 1, combination 2, and combination 3; wherein, the combination 1 is a combination of SCGN, PGP9.5, and S100; the combination 2 is a combination of SCGN and PGP9.5; the combination 3 is a combination of SCGN and S100. The present invention also provides the application of the above biomarker combination in the preparation of a diagnostic reagent for Hirschsprung's disease. At the same time, an immunohistochemistry kit is provided. The present invention discovers that SCGN can effectively identify ganglion cells in rectal mucosal biopsy specimens / entire colon specimens of children with Hirschsprung's disease, and the diagnostic sensitivity and specificity are higher than the existing detection schemes after combining with PGP9.5 and / or S100; the present invention provides a new, accurate, and sensitive detection method for the diagnosis of Hirschsprung's disease.

The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.

The invention discloses lower limb dyskinesia adjusting equipment and a gait adjusting method, and the equipment comprises a wearing part which comprises a housing matched with a lower limb; the projection module comprises a projector arranged on the shell, and the projection angle of the projector is adjustable; the control unit comprises a control mainboard arranged in the shell and an acquisition module communicating with the control mainboard, and the acquisition module is configured to acquire gait data of the wearing piece in real time; the projector communicates with the control mainboard, and the control mainboard is configured to control and adjust the projection angle of the projector based on the gait data acquired by the acquisition module. The lower limb dyskinesia adjusting device prompts gait disorders by using vision, and the mechanism is that the lower limb dyskinesia adjusting device can provide external sensory cues for the patient and stimulate the visual system of the patient, so that neural activity of the premotor area is activated. Visual information is used for guiding gaits, and the deficiency of internal movement rhythm caused by basal ganglion dysfunction is made up.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

The invention discloses Hangzhou white chrysanthemum-derived exosome-like nano-vesicles, a preparation method thereof and application of the nano-vesicles in treatment of optic nerve retinal degeneration diseases. In-vitro experiments show that the Hangzhou white chrysanthemum-derived exosome-like nano-vesicles provided by the invention can effectively inhibit glutamic acid-induced retinal cell oxidative stress and mitochondrial injury and improve the cell activity. In-vivo experiments show that the survival rate of ganglion cells in the retina of an NMDA injury model mouse can be remarkably improved by injecting the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle into a vitreous cavity, and the visual electrophysiological function of the NMDA injury model mouse can be improved. The invention provides a new thought and method for treatment of optic nerve retinal degeneration diseases, and has a wide application prospect. In addition, the preparation method of the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle provided by the invention is simple, and has the advantages of low cost, wide applicability, good safety, no animal-derived components and the like.

The application discloses application of a peripheral nervous system Mas-related G protein-coupled receptor D as a target point in preparation of a medicine for screening for relieving opioid tolerance. Jun The application further provides a medicine composition for regulating opioid tolerance, containing a Mas-related G protein-coupled receptor D siRNA sequence shown in SEQ ID NO. 1 or a siRNA sequence shown in SEQ ID NO. 2. The application further provides an in-situ hybridization kit for detecting expression of a Mas-related G protein-coupled receptor D gene in a dorsal root ganglion tissue of a peripheral nervous system. The application expands a new path for opioid companion diagnosis and intervention.

The embodiment of the invention relates to the technical field of instrument data control, and discloses a non-invasive electrode closed-loop feedback stellate ganglion block electrical stimulation device. According to the device, a control module carries out closed-loop control processing on initial stimulation parameters and carries out adjustment processing on stimulation frequency and intensity to obtain an optimal control parameter combination; the acquisition module performs multi-dimensional acquisition processing on the physiological parameters to obtain a monitoring data set and performs threshold judgment processing to obtain a stimulation control instruction; the analysis module performs dynamic analysis processing on the monitoring data in the stimulation process to obtain a parameter adjustment strategy, and performs optimization processing on the stimulation parameters according to the parameter adjustment strategy to obtain steady-state control parameters; and the evaluation module carries out integration analysis processing on the control process data to obtain a working state evaluation index, and carries out classified statistical processing according to the evaluation index to obtain a parameter optimization suggestion. According to the invention, adaptive adjustment of the stimulation parameters and intelligent evaluation of the system operation state are realized.

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and non-pungent derivatives of capsaicin, in their tautomeric forms and pharmaceutically acceptable salts, as the sole active ingredient, for use in the stimulation of the sphenopalatine ganglion and the enhancement of cerebral blood flow, to prevent or reduce brain injury resulting from decreased cerebral blood flow. The composition is administered via the oral transmucosal route, preferably in the form of a mucoadhesive tablet, and may be formulated for immediate or prolonged release, ensuring effective and tolerable absorption while avoiding the irritant effects associated with pungent capsaicin.

The invention discloses application of a peripheral nervous system Mas related G protein coupled receptor D as a target spot in preparing and screening a medicine for relieving opioid medicine tolerance. The invention also provides a pharmaceutical composition for regulating and controlling the tolerance of the opioid drugs. The pharmaceutical composition contains a Mas related G protein coupled receptor D siRNA sequence as shown in SEQ ID NO. 1 or a Jun siRNA sequence as shown in SEQ ID NO. 2. The invention also provides an in-situ hybridization kit for detecting the expression of the Mas related G protein coupled receptor D gene in the dorsal root ganglion tissue of the peripheral nervous system. According to the invention, a new path for accompanying diagnosis and intervention of opioid drugs is expanded.

A method is provided for stimulating a sphenopalatine ganglion (SPG) of a patient, the method including inserting a tube and an electrode mount into a nasal cavity of the patient and advancing the tube along a floor of the nasal cavity to near a posterior end of an inferior turbinate. One or more electrodes of the electrode mount are deployed superiorly away from the tube while the tube is disposed along the floor of the nasal cavity and the electrode mount is disposed within the nasal cavity, so as to bring at least one of the one or more electrodes into contact with a wall of the nasal cavity. A current configured to stimulate the SPG via the wall is applied to the one or more electrodes. Other embodiments are also described.

The invention relates to the technical field of medical monitoring, and particularly discloses an AI anesthesia depth monitoring system combined with nerve stimulation, which is characterized in that standardized electrical stimulation is applied to a motor nerve pathway of a patient in a general anesthesia state, and spinal nerve electrical signals and limb movement signals induced by the standardized electrical stimulation are synchronously acquired and analyzed; performing time-frequency transformation on the neural signal to extract a dominant oscillation mode of the neural signal, and generating a neural rhythm disorder degree characteristic value by quantizing frequency jitter and amplitude attenuation; analyzing the time sequence collaboration of the motion signal and the stimulation and the motion form, and generating a motion response deviation characteristic value; fusing the two features into a two-dimensional feature vector, inputting the two-dimensional feature vector into a pre-trained anesthesia depth classification model, and directly outputting an objective anesthesia depth level; and finally, starting grading early warning according to the grade change trend and generating a monitoring report.

The present invention relates to the technical field of biomedicine, and relates to a gene therapy vector for ameliorating an eye disease and a use thereof. Specifically, targeted optimization design and screening were carried out on an hRs1 gene coding sequence and a promoter sequence thereof, an rAAV viral vector (rAAV2-hSyn-Kozak-hRS1-bGHpA) expressing the normal human RS1 protein was constructed, and the effectiveness thereof was proven in an Rs1-KO mouse model. Experimental results show that the hRs1 gene, driven by the hSyn promoter, can be highly expressed in a mammal (e.g., human) retinal ganglion cell (RGC), and X-linked retinoschisis can be effectively treated.

Systems, devices, and methods for treating a nerve injury in a patient are provided. A system for treating a patient includes at least one of a nerve graft-conduit or nerve cap-graft comprise a nerve segment derived from a tissue source. Methods for producing a medical device comprising a nerve segment, for obtaining an ideal degree of decellularization of a nerve segment, and for treating a patient with a medical device comprising a nerve segment are provided.

The invention belongs to the technical field of biological medicines, and discloses application of dasatinib in preparation of a medicine for promoting retina ganglion cell axon regeneration and dendritic repair. The research of the invention finds that dasatinib has the effect of promoting RGC axon regeneration and dendritic repair after optic nerve injury. When dasatinib is adopted for treatment, repair and regeneration of retinal ganglion cell axons and dendrites after optic nerve injury can be promoted, and the purpose of treating traumatic optic nerve injury is achieved.

The present disclosure relates to means of treating ocular axis length diseases, such as myopia. The optical films of the present invention include apparatuses and methods for formulating, selecting, supplying and assembling permanent or non-permanent optical films for use with standard monochromatic eyeglasses, where the apparatuses and methods are configured with non-refractive opaque features, wherein the non-refractive opaque feature promotes an increase in the whole retinal ganglion cell activity of the wearer, which can be used as an optical signal to slow, improve, control, inhibit or reduce the speed of myopia progression in the wearer.

The present disclosure relates to means for treating axial length disorders, such as myopia, and includes apparatus and methods for prescribing, selecting, supplying, and fitting permanent or non-permanent optical films for use with standard single-vision eyeglasses, wherein the apparatus and methods are configured with non-refractive opaque features, wherein the non-refractive opaque features promote an increase in retinal ganglion cell activity throughout the wearer's retina, which can be used as an optical signal to slow, improve, control, inhibit, or reduce the rate of myopia progression in the wearer.

The percutaneous puncture balloon device comprises a catheter, the outer side wall, close to the operation end, of the catheter is provided with an inner-layer balloon, and the inner-layer balloon is sleeved with an outer-layer balloon; the catheter comprises a catheter body of a hollow structure, the interior of the catheter body is divided into an upper cavity and a lower cavity through a partition plate, the side wall face of the upper cavity is provided with an inner ventilation opening communicated with the inner-layer balloon, and the side wall face of the lower cavity is provided with an outer ventilation opening communicated with the outer-layer balloon. A rotary cavity switching mechanism is arranged at the end, away from the balloon, of the partition plate and used for switching between the upper cavity and the lower cavity. The inner-layer balloon comprises a balloon body, and an elastic binding film layer is arranged in the middle of the balloon body. The traditional Chinese medicine composition has the characteristic of effectively improving the curative effect of a patient suffering from pain in the third branch area.

In some embodiments, disclosed herein are systems and methods of treating a patient that can include the steps of accessing the sphenopalatine fossa, and cannulating the inferior orbital fissure from the sphenopalatine fossa to access the retro-orbital space. The sphenopalatine fossa can be accessed via various routes, including percutaneously. Accessing the sphenopalatine fossa can include the step of inserting a needle-catheter system into the sphenopalatine fossa. Integrated needle-catheter systems as described herein can also be configured to access the trigeminal ganglion, epidural space, intrathecal space, and other desired anatomical locations.

Disclosed are compositions including a population of human enteric neural stem cells (ENSCs), wherein the population comprises at least one of a cell expressing nerve growth factor receptor (NGFR), a cell expressing integrin alpha 6 (ITGA6), a cell expressing L1 cell adhesion molecule (L1CAM), a cell that expresses proteolipid protein 1 (PLP1), and / or a cell that expresses paired-like homeobox 2B (PHOX2B), methods of producing the compositions, and their uses.

Viral constructs and methods of their use in the treatment of diseases and disorders mediated by reduced ELP1 expression are provided. The viral constructs include a coding sequence for human ELP1 under control of a heterogenous promoter (such as a small nuclear RNA promoter), allowing for an increase in ELP1 protein expression in neuron cells of the central nervous system, including for instance retinal cells. Methods of using such viral constructs to protect neural cells, for instance by reducing death of retinal ganglion cells, are also provided.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

The invention provides a prevention and control film for inhibiting eye axis growth and prevention and control glasses, and belongs to the technical field of myopia prevention. The light-transmitting diaphragm comprises a light-transmitting diaphragm and circular units arranged on the surface of the light-transmitting diaphragm in an array mode, each circular unit is of a concave-convex or concave-convex structure, the thickness of the light-transmitting diaphragm ranges from 0.9 mm to 1.1 mm, the diameter of each circular unit ranges from 180 micrometers to 190 micrometers, the distance between the circle centers of every two adjacent circular units ranges from 500 micrometers to 510 micrometers, and the distance between the circle centers of every two adjacent circular units ranges from 500 micrometers to 510 micrometers. A concave-convex structure on the prevention and control film can scatter and refract incident light to form atomization distribution, the discharge frequency of M-type retinal ganglion cells can be inhibited, retinal dopamine release can be promoted, then the activity of sclera fibroblasts is affected, and ocular axis growth is delayed. According to the invention, the excessive growth of the eye axis can be inhibited, so that the effect of increasing the hyperopia reserve of children or inhibiting the development of myopia is achieved.

To provide a novel prophylactic or therapeutic for GM1 gangliosidosis, and a novel composition for preventing or treating GM1 gangliosidosis.SOLUTION: Provided is a prophylactic or therapeutic for GM1 gangliosidosis, comprising, as an active ingredient, at least one selected from the group consisting of amodiaquine, acacetin, sulfamerazine, ungerine, amiodarone, sertindole, delcorine, perphenazine, althiazide, diethylstilbestrol, thiethylperazine, harmol, skimmianine, succinylsulfathiazole, phillalbine, canavanine, harmaline, trihexyphenidyl, fluoxetine, lovastatin, haloperidol, prenylamine lactate, bromperidol, convolvamine, and miglustat, and pharmaceutically acceptable salts thereof, or solvates thereof.SELECTED DRAWING: Figure 5